Journal: International Journal of Ophthalmology

Article Title: Apolipoprotein A1 suppresses the hypoxia-induced angiogenesis of human retinal endothelial cells by targeting PlGF

doi: 10.18240/ijo.2023.01.05

Figure Lengend Snippet: Ctrl: Normal control group; EC: Empty vector control group; OP: ApoA1 overexpression group; VEGF: Vascular endothelial growth factor; PlGF: Placental growth factor; HRECs: Human retinal vascular endothelial cells. aP<0.05, bP<0.002.

Article Snippet: Cell Culture and Treatment Human retinal vascular endothelial cells (HRECs) were purchased from Angioproteomie (Boston, MA, USA).

Techniques: Control, Plasmid Preparation, Over Expression

Journal: International Journal of Ophthalmology

Article Title: Apolipoprotein A1 suppresses the hypoxia-induced angiogenesis of human retinal endothelial cells by targeting PlGF

doi: 10.18240/ijo.2023.01.05

Figure Lengend Snippet: Ctrl: Normal control group; EC: Empty vector control group; OP: ApoA1 overexpression group; HRECs: Human retinal vascular endothelial cells. cP<0.0001.

Article Snippet: Cell Culture and Treatment Human retinal vascular endothelial cells (HRECs) were purchased from Angioproteomie (Boston, MA, USA).

Techniques: Control, Plasmid Preparation, Over Expression

Journal: International Journal of Ophthalmology

Article Title: Apolipoprotein A1 suppresses the hypoxia-induced angiogenesis of human retinal endothelial cells by targeting PlGF

doi: 10.18240/ijo.2023.01.05

Figure Lengend Snippet: Ctrl: Normal control group; EC: Empty vector control group; OP: ApoA1 overexpression group; HRECs: Human retinal vascular endothelial cells. aP<0.05, cP<0.0001.

Article Snippet: Cell Culture and Treatment Human retinal vascular endothelial cells (HRECs) were purchased from Angioproteomie (Boston, MA, USA).

Techniques: Control, Plasmid Preparation, Over Expression

Journal: International Journal of Ophthalmology

Article Title: Apolipoprotein A1 suppresses the hypoxia-induced angiogenesis of human retinal endothelial cells by targeting PlGF

doi: 10.18240/ijo.2023.01.05

Figure Lengend Snippet: Ctrl: Normal control group; EC: Empty vector control group; OP: ApoA1 overexpression group; PlGF: Placental growth factor; HRECs: Human retinal vascular endothelial cells; MEK: Mitogen-activated protein kinase kinase. aP<0.05, bP<0.002, cP<0.0001, ns: Not significant.

Article Snippet: Cell Culture and Treatment Human retinal vascular endothelial cells (HRECs) were purchased from Angioproteomie (Boston, MA, USA).

Techniques: Control, Plasmid Preparation, Over Expression

Journal: International Journal of Retina and Vitreous

Article Title: Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits

doi: 10.1186/s40942-020-00235-y

Figure Lengend Snippet: ERG analysis of NZW rabbits as a function of time after intravitreal injections. a The effects of the intravitreal PRO-169 (white bars) and ranibizumab (dark bars) on the dark-adapted ERG responses after 30 days of each injection. The dark-adapted retinal response is represented by the mean ± SEM V Max ratio of the ERG (b-wave). b Time dependent effects of repeated injections of PRO-169 and ranibizumab on retinal function of rabbits. The difference of the log semi saturation constant (experimental-control) is represented by the mean ± SEM. V Max ratios are around 1 and log σ differences are around 0, indicating no damage to the road system

Article Snippet: PRO-169 is a recombinant, humanized anti-VEGF-A mAb with a molecular mass of 149 kDa, structurally similar and with a target specificity like bevacizumab (Avastin, Genentech, South San Francisco, CA) [ , ].

Techniques: Injection

Journal: International Journal of Retina and Vitreous

Article Title: Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits

doi: 10.1186/s40942-020-00235-y

Figure Lengend Snippet: Histologic examination of the central retina for PRO-169 ( a ) vs ranibizumab ( b ) after the 1st Ivt injection (D32), for PRO-169 ( c ) vs ranibizumab ( d ) after the 2nd Ivt injection (D63), and for PRO-169 ( e ) vs ranibizumab ( f ) after the 3rd Ivt injection (D94). No retinal toxicity was found in any eyes (x40)

Article Snippet: PRO-169 is a recombinant, humanized anti-VEGF-A mAb with a molecular mass of 149 kDa, structurally similar and with a target specificity like bevacizumab (Avastin, Genentech, South San Francisco, CA) [ , ].

Techniques: Injection

Journal: Journal of Pharmaceutical Analysis

Article Title: SUMO1 regulates post-infarct cardiac repair based on cellular heterogeneity

doi: 10.1016/j.jpha.2022.11.010

Figure Lengend Snippet: SUMO1 inhibited VEGFA signaling in endothelial cells and restrained neovascularization. (A) Heatmap showing logarithmic interaction scores between all cell subsets. (B, C) Unique ligand-receptor interactions (B), and the specific ligand-receptor pair (C) for all cell subclusters. (D) Schematic overview of SUMO1 knockdown/overexpression experiments in proliferative HUVEC. (E) The SUMO1 mRNA levels after transfected SUMO1 plasmid ( n = 6). Data expressed as fold change of SUMO1/GAPDH vs. Sham. (F, G) Cell scratch assay was used to measure EC migration (F), and wound healing (% closure) was quantified ( n =6) (G). (H, I) Representative images of EC tube formation (H), and number of branches (left) and tubes (right) were quantified ( n =6) (I). (J , K) Cell cycle analysis by propidium iodide staining and flow cytometry for HUVEC (J), and percentage of HUVEC in G2/M phase of the cell cycle ( n =6) (K). Mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Ctrl or siCtrl. VEGFA: vascular endothelial growth factor A; HUVEC: human umbilical vein endothelial cell; CM: cardiomyocyte; EC: endothelial cell; Ctrl: Control.

Article Snippet: Recombinant human VEGFA (# P00063; Solarbio) was used at 10 ng/mL for HUVEC treatment.

Techniques: Knockdown, Over Expression, Transfection, Plasmid Preparation, Wound Healing Assay, Migration, Cell Cycle Assay, Staining, Flow Cytometry, Control

Journal: Journal of Pharmaceutical Analysis

Article Title: SUMO1 regulates post-infarct cardiac repair based on cellular heterogeneity

doi: 10.1016/j.jpha.2022.11.010

Figure Lengend Snippet: Potential mechanisms of SUMO1 in different heart cell types after myocardial infarction (MI). In cardiomyocytes, SUMO1 represses Nppa and Nppb transcription and reduces the distribution of Nppa + Nppb + cardiomyocyte (CM) in injured myocardium in a JunD-dependent manner after MI. In fibroblasts, SUMO1 mediated cardiac repair, promoting the conversion of proliferating fibroblasts to collagen-secreting fibroblasts after myocardial damage. In endothelial cells, SUMO1 inhibited vascular endothelial growth factor A (VEGFA)-mediated angiogenic signaling and inhibited FABP + endothelial cell (EC) proliferation and revascularization after MI.

Article Snippet: Recombinant human VEGFA (# P00063; Solarbio) was used at 10 ng/mL for HUVEC treatment.

Techniques: